Highlights
- 4DMedical Limited expands clinical use of CT:VQ™ at Cleveland Clinic in the U.S.
- Racura Oncology appoints Beyond Drug Development for HARNESS-1 trial in NSCLC patients.
- Both 4DX and RAC stocks record gains despite broader S&P/ASX 200 Health Care index decline.
In 2025, select ASX-listed health care stocks recorded gains while the broader S&P/ASX 200 Health Care index declined 25.4% over the year. 4DMedical Limited rose 743.8% year-to-date, and Racura Oncology increased 99.3%. These movements reflect differences in individual company performance within the Australian health care sector.
|
Name |
Ticker |
CMP in AUD (as on 29 Dec 2025) |
6-Month Change |
9-Month Change |
YTD-Month Change |
|
4DMedical Limited |
4.05 |
1553.06% |
1457.69% |
743.75% |
|
|
Racura Oncology |
2.69 |
129.91% |
133.91% |
99.26% |
Cleveland Clinic Begins Clinical Use of 4DMedical’s CT:VQ™
4DMedical Limited (ASX:4DX) is a medical technology company developing advanced imaging and AI solutions for respiratory care. Its patented XV Technology® converts standard scans into detailed functional insights to support earlier detection and monitoring of lung disease.
19 December 2025 – 4DMedical Limited has announced that Cleveland Clinic has entered a commercial arrangement for the clinical use of its CT:VQ™ technology. Cleveland Clinic becomes the third major U.S. academic medical centre to adopt CT:VQ™, following Stanford University and the University of Miami.
The agreement includes a one-month introductory pricing period before full commercial terms, enabling integration into clinical workflows. This deployment adds to 4DMedical’s network of academic medical centres using CT:VQ™ for respiratory diagnostics. The adoption within three months of FDA clearance highlights the early uptake of the technology across prominent U.S. hospitals, and Cleveland Clinic will serve as a reference site for assessing clinical and operational applications.
Racura Oncology Engages Beyond Drug Development for HARNESS-1 Trial
Racura Oncology (ASX:RAC) is a Phase 3 biopharmaceutical company focused on developing RCDS1, a small molecule targeting MYC to treat cancer.
24 December 2025 – Racura Oncology Limited has appointed Beyond Drug Development to support the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
The trial, to be conducted across five sites in Australia, aims to evaluate safety, tolerability, pharmacokinetics, optimal dosage, and preliminary efficacy, with the first patient expected to be recruited in Q1 2026, subject to governance approval. Beyond, an Australian CRO with extensive experience, will provide clinical trial management under a Master Service Agreement valued at approximately AUD 3.05 million, covering up to 80 patients.






Please wait processing your request...